Compare Amylx Pharmaceuticals Inc (AMLX) vs SMX Security Matters plc (SMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs SMX Security Matters plc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while SMX Security Matters plc trades at $15.67 (market cap $15.03M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 131.7× SMX Security Matters plc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| AMLX | SMX | |
|---|---|---|
Market Cap | $1.98B | $15.03M |
Sector | Health | Technology |
52-Week High | $18.70 | $313.26K |
52-Week Low | $7.64 | $12.87 |
Enterprise Value | $1.70B | $12.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SMX trades at $15.65, down 4.02% in the last session, with a neutral technical signal and bearish moving averages. The stock shows negative profitability with a ROE of -2,216.26% and ROA of -398.22%, while the P/B ratio stands at 1.7. Recent corporate actions include two reverse stock splits in May and June 2026. News highlights the company's focus on recycled plastic traceability amid new state recycling mandates, positioning it in a growing regulatory environment.
The outlook for SMX is challenged by weak profitability but supported by potential demand from recycling regulations. Investment opportunity lies in policy-driven adoption of its traceability technology, while risks include execution hurdles and sustained negative returns. The stock's near-term direction may hinge on converting regulatory tailwinds into tangible financial improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
